In:
The Prostate, Wiley, Vol. 83, No. 12 ( 2023-09), p. 1186-1192
Abstract:
We evaluated 18 F‐DCFPyL test–retest repeatability of uptake in normal organs. Methods Twenty‐two prostate cancer (PC) patients underwent two 18 F‐DCFPyL PET scans within 7 days within a prospective clinical trial (NCT03793543). In both PET scans, uptake in normal organs (kidneys, spleen, liver, and salivary and lacrimal glands) was quantified. Repeatability was determined by using within‐subject coefficient of variation (wCOV), with lower values indicating improved repeatability. Results For SUV mean , repeatability was high for kidneys, spleen, liver, and parotid glands (wCOV, range: 9.0%–14.3%) and lower for lacrimal (23.9%) and submandibular glands (12.4%). For SUV max , however, the lacrimal (14.4%) and submandibular glands (6.9%) achieved higher repeatability, while for large organs (kidneys, liver, spleen, and parotid glands), repeatability was low (range: 14.1%–45.2%). Conclusion We found acceptable repeatability of uptake on 18 F‐DCFPyL PET for normal organs, in particular for SUV mean in the liver or parotid glands. This may have implications for both PSMA‐targeted imaging and treatment, as patient selection for radioligand therapy and standardized frameworks for scan interpretation (PROMISE, E‐PSMA) rely on uptake in those reference organs.
Type of Medium:
Online Resource
ISSN:
0270-4137
,
1097-0045
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1494709-2